Investing in This Healthcare Stock Could Be Like Catching Nvidia at the Dawn of the AI Boom
https://www.fool.com/investing/2024/09/22/investing-in-this-healthcare-stock-could-be-like/?source=iedfolrf0000001
Sep 22, 2024 - Nvidia has been the hottest stock since the start of the AI revolution, and I see one particular healthcare business following a similar trajectory.
0
Prediction: This Is What Eli Lilly Stock Will Do Next (Hint: It's Not a Stock Split)
https://www.fool.com/investing/2024/09/21/prediction-what-eli-lilly-stock-will-do-next/?source=iedfolrf0000001
Sep 21, 2024 - History shows that Eli Lilly tends to do something special with its stock toward the end of the year.
0
Prediction: This Will Be the First Healthcare Stock to Join the Trillion-Dollar Club
https://www.fool.com/investing/2024/09/17/prediction-this-will-be-the-first-healthcare-stock/?source=iedfolrf0000001
Sep 17, 2024 - Most trillion-dollar companies today are in the technology sector, but one particular healthcare stock is knocking on the door of a trillion-dollar valuation.
0
NVO Oral Obesity Pill Tops Wegovy; LLY, VKTX, GPCR Stocks Rise
https://www.zacks.com/stock/news/2335487/nvo-oral-obesity-pill-tops-wegovy-lly-vktx-gpcr-stocks-rise?cid=CS-ZC-FT-analyst_blog|industry_focus-2335487
Sep 12, 2024 - Stocks of LLY, VKTX and GPCR, which make oral pills for obesity, rose on Wednesday in response to Novo Nordisk's positive data.
0
4 No-Brainer Stock Splits to Buy Now
https://www.fool.com/investing/2024/09/11/4-no-brainer-stock-splits-to-buy-now/?source=iedfolrf0000001
Sep 11, 2024 - There's a massive reason these stocks should split now.
0
Top Stock Reports for Visa, AbbVie & Anheuser-Busch
https://www.zacks.com/commentary/2334072/top-stock-reports-for-visa-abbvie-anheuser-busch?cid=CS-ZC-FT-research_daily-2334072
Sep 10, 2024 - Today's Research Daily features new research reports on 16 major stocks, including Visa Inc. (V), AbbVie Inc. (ABBV) and Anheuser-Busch InBev SA/NV (BUD), as well as two micro-cap stocks Servotronics, Inc. (SVT) and United-Guardian, Inc. (UG).
0
Terns Stock Soars on Positive Data From Phase I Study of Obesity Drug
https://www.zacks.com/stock/news/2334185/terns-stock-soars-on-positive-data-from-phase-i-study-of-obesity-drug?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-2334185
Sep 10, 2024 - TERN stock soars on positive data from the early-stage study of TERN-601 for obesity, showing statistically significant weight reduction compared to placebo.
0
Best Momentum Stocks to Buy for September 10th
https://www.zacks.com/commentary/2333720/best-momentum-stocks-to-buy-for-september-10th?cid=CS-ZC-FT-zacks_1_rank_additions|momentum_additions-2333720
Sep 10, 2024 - LLY, MCO, and BCH made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on September 10, 2024.
0
MRK Stock Dips After SMMT's Cancer Drug Outshines Keytruda in Study
https://www.zacks.com/stock/news/2334056/mrk-stock-dips-after-smmt-s-cancer-drug-outshines-keytruda-in-study?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-2334056
Sep 10, 2024 - Merck's Keytruda is the standard of care for NSCLC. Ivonescimab, however, shows clinically meaningful benefit over Keytruda in a phase III study in NSCLC.
0
Bayer Reports Encouraging NSCLC Drug Data, Gets Approval for Eylea 8mg
https://www.zacks.com/stock/news/2334045/bayer-reports-encouraging-nsclc-drug-data-gets-approval-for-eylea-8mg?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-2334045
Sep 10, 2024 - BAYRY's NSCLC drug BAY 2927088 shows an encouraging safety profile in the expansion part of the ongoing study. The company also announces the approval of Eylea 8mg.
0